Kymera Therapeutics, Inc. KYMR
111.95
(3.86)
(3.33%)
as of 25 Sep
- Market cap
- $9.7B
- P/E
- 0.0×
Follow KYMR
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | 0.00 | 31.61 | 41.83 | 28.61 | 18.83 | 64.14 | 167.66 |
P/FCF ratio |
— | — | 0.00 | 13.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | (5.84) | (53.60) | (79.44) | (33.89) | 183.91 | (48.86) | (98.49) |
P/B ratio |
— | — | 0.00 | 3.79 | 6.63 | 2.73 | 3.75 | 3.61 | 4.16 |
Price to Tangible BV |
— | — | 0.00 | 3.79 | 6.63 | 2.73 | 3.75 | 3.61 | 4.16 |
EV/Sales |
— | — | 0.00 | 22.92 | 35.77 | 19.94 | 14.07 | 53.80 | 146.07 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 4.34 | 8.85 | (20.21) | (6.10) | (10.76) | (13.02) | (24.59) |
EV/FCF |
— | — | 2.13 | 9.87 | (19.96) | (5.99) | (8.05) | (12.21) | (24.44) |
Quick Ratio |
— | 8.83 | 2.66 | 2.68 | 4.78 | 5.74 | 4.55 | 7.21 | 10.19 |
Current Ratio |
— | 8.92 | 2.69 | 2.73 | 4.88 | 5.88 | 4.73 | 7.53 | 10.47 |
Net Debt/EBITDA |
— | 1.91 | 2.19 | 6.88 | 4.78 | 2.58 | 2.23 | 1.81 | 2.42 |
Debt/Assets |
0.00% | 1.57% | 1.00% | 0.12% | 0.19% | 0.21% | 0.23% | 0.23% | 0.08% |
Debt/Equity |
— | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.04 | 0.11 | 0.13 | 0.08 | 0.13 | 0.06 | 0.03 |
Operating CF/Net income |
— | 0.83 | (0.43) | (1.61) | 1.29 | 0.99 | 0.70 | 0.87 | 0.75 |
Capex/Depreciation |
— | 0.00 | (0.64) | (2.73) | (0.19) | (0.73) | 20.72 | 1.94 | 2.56 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 39.45% | 75.79% | (52.17%) | (26.96%) | (32.60%) | (33.21%) | (36.38%) | (25.78%) | |
| — | (97.07%) | (51.26%) | (18.10%) | (18.34%) | (25.61%) | (24.93%) | (28.81%) | (22.89%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (342.22%) | (119.65%) | (483.64%) | (46.84%) | (29.80%) |
Return on Tangible Assets |
— | (54.56%) | (66.45%) | (26.98%) | (27.04%) | (42.83%) | (39.96%) | (45.41%) | (37.46%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 6.19 | 0.68 | 19.78 | 69.66 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 1,266.46% | 182.48% | 188.13% | 350.76% | 240.59% | 510.38% | 807.34% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 272.02% | 53.57% | 49.90% | 93.61% | 70.03% | 134.97% | 173.90% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 40.76% | 15.25% | 34.29% | 75.77% | 54.86% | 116.87% | 152.77% |
Graham Net Nets |
— | — | 1.39 | 0.09 | 0.10 | 0.23 | 0.15 | 0.12 | 0.11 |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (0.78%) | (21.39%) | (3.24%) | (11.59%) | (9.94%) | (7.38%) | (4.73%) |
Free Cash Flow Yield |
— | — | (17.03%) | 7.35% | (4.28%) | (11.64%) | (9.28%) | (6.87%) | (3.56%) |
Revenue per Share |
— | 0.00 | 1.73 | 1.96 | 1.52 | 0.87 | 1.35 | 0.63 | 0.46 |
Operating CF per Share |
— | (0.40) | 10.54 | 5.08 | (2.69) | (2.84) | (1.76) | (2.59) | (2.76) |
Capex per Share |
— | 0.00 | (0.31) | (0.52) | (0.03) | (0.05) | (0.59) | (0.17) | (0.02) |
Free Cash Flow per Share |
— | (0.40) | 10.23 | 4.56 | (2.72) | (2.89) | (2.35) | (2.76) | (2.77) |
Cash per Share |
— | 0.93 | 54.12 | 17.07 | 9.22 | 7.55 | 6.42 | 6.51 | 10.04 |
Shareholders Equity per Share |
— | 0.88 | 20.41 | 16.36 | 9.58 | 9.09 | 6.77 | 11.14 | 18.70 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.88 | 20.41 | 16.36 | 9.58 | 9.09 | 6.77 | 11.14 | 18.70 |
Free Cash Flow |
— | (17.86) | 17.37 | 79.03 | (130.54) | (155.92) | (137.31) | (207.34) | (234.34) |
Working Capital |
— | 37.10 | 58.28 | 191.72 | 358.73 | 348.07 | 319.63 | 442.50 | 788.00 |
Capital Expenditures |
— | (1.36) | (0.53) | (9.10) | (1.60) | (2.84) | (34.48) | (12.84) | (1.45) |
Net Current Asset Value |
— | 36.55 | 10.82 | 99.05 | 305.01 | 306.43 | 224.53 | 367.85 | 708.07 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.18 | 0.27 | 0.02 | 0.06 | 0.44 | 0.27 | 0.04 |
Net Profit Margin |
— | 0.00% | (1,405.79%) | (160.55%) | (137.60%) | (330.60%) | (186.99%) | (475.57%) | (794.04%) |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.09 | 0.22 | 0.31 | 0.69 | 0.29 | (0.03) | (0.13) | (0.01) |
Cash ROIC |
— | (24.84%) | 11.04% | 13.31% | (15.59%) | (18.52%) | (19.58%) | (18.47%) | (11.36%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 93.89 | 204.58 | 35.05 | 8.96 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 3,660.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.79 | — | 0.36 | 0.36 | 1.34 | 8.77 | — | — |
Average Payables |
— | 2.67 | 2.67 | 3.82 | 4.19 | 4.17 | 5.71 | 6.53 | 5.00 |
Average Assets |
— | 22.12 | 80.47 | 301.94 | 546.54 | 604.52 | 589.45 | 776.90 | 1,360.42 |
Average Common Equity |
— | (54.42) | (54.42) | 104.74 | 371.76 | 474.89 | 442.56 | 615.29 | 1,207.64 |
Columns are period end dates